Amarin | AMRN - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
AbbVie USD 41.64B 458M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Amarin USD 164.2M 15.45M 2026-06
AstraZeneca USD 31.55B 1.02B 2026-06
BioCryst Pharmaceuticals USD 208.85M 13.46M 2026-06
DBV Technologies USD 54.3M 2.5M 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
Halozyme Therapeutics USD 344.44M 18.77M 2026-06
Heron Therapeutics USD 92.14M 1.63M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06